Up­dat­ed: FDA re­port rais­es con­cerns over Sarep­ta Duchenne gene ther­a­py ahead of ac­cel­er­at­ed ap­proval de­ci­sion

Ahead of what’s cer­tain to be a close­ly watched ad­vi­so­ry com­mit­tee meet­ing Fri­day, the FDA out­lined con­cerns on the ef­fi­ca­cy and safe­ty of Sarep­ta Ther­a­peu­tics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER